UC Scientists Awarded $1.7 Million for Low Back Pain Research
CINCINNATIThe National Institute of Neurological Disorders and Stroke has awarded $1.7 million to University of Cincinnati (UC) anesthesiology researchers to study a condition that costs Americans $50 billion a yearlow back pain.
Back pain is the leading cause of disability in Americans younger than 45 years old and is experienced by 50 to 80 percent of adults at some point in their lives. Back pain becomes chronic if it persists for more than three months and the cause can sometimes be difficult to determine.
The UC researchers are focusing their five-year study on inflammation and how its effects on sensory neurons in the low back cause persistent chronic pain.
The team, led by Jun-Ming Zhang, MD, director of UCs
If we can determine the role these chemokines play in the development of back pain we can hopefully develop better medications to treat the problem, says Zhang.
Zhang says acute (short-term) pain can actually be beneficial. Acute pain responses to potentially dangerous stimulilike the neural circuitry that tells you to pull your hand away from a hot stoveare essential for survival, says Zhang.
But when pain becomes chronic, it serves no useful purpose, he says, and often affects a persons quality of life.
Back pain can be caused by physical trauma such as a sports injury, lifting heavy items or from a car accident, Zhang explains. For others, medical conditions such as a herniated disc cause pain. But many people experience back pain for no apparent reason.
When a patient goes to the doctor for low back pain, they may undergo an MRI or an X-ray. Sometimes these tests show anatomical reasons for the pain such as a herniated disc. But for some patients, tests dont show any physical evidence for why they are experiencing low back pain, he says.
Zhang adds that the lack of physical evidence can be very frustrating for patients and make it more difficult for doctors to help a patient effectively manage their pain through medication and other treatment therapies.
Thats why we hope to identify specific molecules that contribute to low back pain development. Our goal is to develop a non-opiod analgesic targeting those molecules to alleviate pain, says Zhang.
In previous research, Zhang and his team, including Judith Strong, PhD, co-investigator for the new study, found that pain-sensing neurons can become abnormally sensitive or fire spontaneously in the absence of stimuli. This early spontaneous activity plays a key role in setting up the pathological pain state.
We found that by blocking the early spontaneous activity of an injured nerve we can completely prevent the development of chronic pain. This technique could be extremely useful for combat nerve injuries and amputations that often lead chronic pain, he says.
In the new study, the team will explore how inflammation may contribute to the development of low back pain by intentionally causing this abnormal neuronal firing.
Judith Strong, PhD, and Jun-Ming Zhang, MD, study chronic low back pain.
Jun-Ming Zhang, MD
Judith Strong, PhD
Tags
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.